Abbvie Inc.

Abbott Laboratories Corporation

Abbott Products Gmbh

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Dachun Liu

John K Pratt

Todd Warren Rockway

Clarence J Maring

David A Betebenner

Rolf Wagner

Allan C Krueger

Douglas K Hutchinson

Warren M Kati

Pamela L Donner

Michael D Tufano

John T Randolph

David A DeGoey

Charles A Flentge

Keith F McDaniel

Christopher E Motter

Kent D Stewart

Kenton L Longenecker

Yi Gao

Le Wang

George S Sheppard

Lisa A Hasvold

William A Carroll

Kevin R Woller

Yaya Liu

Charles W Hutchins

Sachin V Patel

Tammie K Jinkerson

Mark A Matulenko

Ryan G Keddy

Kathy A Sarris

Seble H Wagaw

Lissa T Nelson

Wenke Li

Mary E Bellizzi

Daniel D Caspi

David A Degoey

Brian E Green

Geoff G Z Zhang

William J McClellan

Shuang Chen

James H Holms

Darold L Madigan

Xiaochun Lou

Jean C Califano

Anthony Ralph Haight

David M Barnes

Larry L Klein

Ming Clinton Yeung

Geoff G Zhang

Yujia Dai

Brian J Kotecki

Steven D Fidanze

Dale J Kempf

Rong Zhang

Uwe Schoen

Curt S Cooper

Jason P Shanley

Vincent S Stoll

David D Anderson

Carol K Wada

Axel Pahl

Teresa A Rosenberg

Daniel P Larson

Todd D Bosse

Rodger F Henry

Robert A Mantei

Thomas B Borchardt

Tami J Pilot-Matias

Steven Elmore

Michael D Wendt

Michael R Schrimpf

David J Grampovnik

M Robert Leanna

Hui-Ju J Chen

Russell Drew Cink

Peggy Huang

Robert Hubbard

Chang H Park

Mira Hinman

Liangjun Lu

Richard D Bishop

Jean-Christophe C Califano

Robert J Carrick

Bradley D Gates

John E Hengeveld

Hongmei Mo

Wenping He

Nobuhiko Iwasaki

Akhteruzzaman Molla

Sherie V L Masse

Jasmina Marjanovic

Todd M Hansen

Robin R Frey

Andrew Bogdan

Justin D Dietrich

William J Flosi

Preethi Krishnan

Todd N Soltwedel

The present invention provides for compounds of formula (I) wherein R, R, R, R, R, X, and Xhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Bromodomain inhibitors

The present invention provides for compounds of formula (I). wherein R, R, R, L, G, A, A, A, and Ahave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I). 

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

The present invention provides for compounds of formula (I) wherein R, X, Y, Y, L, A, A, A, A, A, A, A, and A, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I). 

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided. 

The present invention provides for compounds of formula (I) wherein A, Y, J, R, R, and Rhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.

Isoindolone derivatives

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Antiviral compounds and uses thereof

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Hepatitis C inhibitors and uses thereof

The present invention provides for compounds of formula (I) wherein A, A, A, A, J, and Xhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.

Pyridinone and pyridazinone derivatives

The present invention provides for compounds of formula (I) wherein R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Pyrrole-3-carboxamide bromodomain inhibitors

The present invention provides for compounds of formula (I) wherein R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Dihydro-pyrrolopyridinone inhibitors

Growing community of inventors

Vernon Hills, IL, United States of America

Dachun Liu